The total return over the past 12 months is -48.74% vs. +16.94% for the S&P 500. So far it's up -70.53% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (48.74%) | (32.73%) | (48.18%) | N/A | N/A | N/A |
| Total Return CAGR | (48.74%) | (32.73%) | (48.18%) | N/A | N/A | N/A |
| Revenue CAGR | (55.00%) | (91.77%) | (68.32%) | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Lyell Immunopharma, Inc. (LYEL)
| Year | Start price | End price | LYEL Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $30.78 | $9.07 | (70.53%) | +14.51% | (85.04%) |
| 2025 | $12.80 | $30.78 | +140.47% | +17.72% | +122.75% |
| 2024 | $38.80 | $12.80 | (67.01%) | +24.89% | (91.90%) |
| 2023 | $69.40 | $38.80 | (44.09%) | +26.19% | (70.28%) |
| 2022 | $154.80 | $69.40 | (55.17%) | (18.17%) | (37.00%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
